Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 4491-4495, September 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kar, R.
Right arrow Articles by Wile, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kar, R.
Right arrow Articles by Wile, A. G.

Pharmacokinetics of 5-Fluorouracil in Rabbits in Experimental Regional Chemotherapy

Rita Kar, Robert A. Cohen, Theresa M. Terem, Maurice Y. Nahabedian and Alan G. Wile1

Department of Surgery, University of California, Irvine Medical Center, Orange, California 92668

The goal of this study was to identify the mode(s) of regional administration of 5-fluorouracil (5-FUra) with the greatest pharmacological advantage in an animal model. Parameters examined were the amount of systemic exposure to 5-FUra and plasma and tissue levels of 5-FUra. Anesthetized New Zealand white rabbits bearing a VX-2 carcinoma in the thigh received 5-FUra (20 mg/kg body weight) by the following routes: i.v., intraarterial (i.a.), i.a. with stopflow, i.a. with outflow occlusion, and isolation perfusion (IP). Serial venous blood samples were obtained prior to and after drug administration for a total of 45 min. A similar sampling of the perfusion circuit was conducted in those animals undergoing IP. At the end of the sampling period tumor and adjacent normal muscle were obtained. Plasma and tissue levels of 5-FUra were determined by a high pressure liquid chromatographic method. It was observed that systemic exposure to 5-FUra was identical for the i.v., i.a., i.a. with stopflow, and i.a. with outflow occlusion groups. Systemic exposure to 5-FUra in the IP group was only 0.30 of that observed for the i.a. group. Tissue 5-FUra levels in the i.v., i.a., and i.a. with stopflow groups were low and comparable to one another. Tissue levels of the 5-FUra were significantly higher in the i.a. with outflow occlusion and IP groups. We conclude that only selected forms of regional administration of 5-FUra offer pharmacological advantage when compared to systemic administration.

1 To whom requests for reprints should be addressed, at Department of Surgery, University of California Irvine Medical Center, 101 City Drive South, Orange, CA 92668

Received 5/17/85. Revised 8/16/85. Revised 4/24/86. Accepted 6/ 4/86.




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Heil, T. Ziegelhoeffer, F. Pipp, S. Kostin, S. Martin, M. Clauss, and W. Schaper
Blood monocyte concentration is critical for enhancement of collateral artery growth
Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2411 - H2419.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.